$89MSeries B, 26 March 2026
Series B to take lead oral peptide programs into clinical proof of concept.
- Amount
- $89M
- Stage
- Series B
- Announced
- 26 March 2026
- Lead
- LAV
- Other investors
- Foresite Capital, Quan Capital, Hankang Capital, RA Capital, Logos Capital, OrbiMed
- Use of funds
- Series B to take lead oral peptide programs into clinical proof of concept.
- Checked
- Announced by the company
- Sources
- Pinnacle Medicines raises $89M Series B biospace.com
Pinnacle Medicines raises $89M Series B pulse2.com